Professional Experience

• Former Executive Vice President, CFO, and COO, Baxalta, Inc. (July 2015 – July 2016) (spun off from Baxter International, Inc. in 2015; acquired by Shire plc in 2016)
• Former Corporate Vice President and CFO, Baxter International, Inc. (2010 – June 2015) and previously held various leadership roles in finance across multiple divisions since joining in 1989

Key Skills & Qualifications

• Management and Leadership Experience: decades of executive and operational experience in the biopharmaceutical and medical device sectors, including as former Executive Vice President, CFO, and COO of Baxalta, Inc. and Corporate Vice President and CFO of Baxter International, Inc. Mr. Hombach served as a member of the executive leadership team responsible for finance, accounting, IT, treasury, tax, investor relations, and all aspects of operations (manufacturing, quality, supply chain, and procurement) at Baxalta, Inc. and served as an advisor to the CEO on strategy, M&A, and operational execution
• Finance and Accounting: Certified Public Accountant (CPA) with extensive knowledge and experience in finance and accounting matters, with six years of public CFO service, having served as CFO of Baxalta, Inc. and Baxter International, Inc. Mr. Hombach previously held various leadership roles in finance across multiple divisions since joining Baxter International, Inc. in 1989
• Strategic Transformation: gained through experience as the former Corporate Vice President and CFO of Baxter International, Inc.; Mr. Hombach was a key architect of the rationale and strategy to split Baxter International, Inc. and Baxalta, Inc. into two companies
• Corporate Strategy/M&A: led multiple M&A and other financial transactions common in health care at both the board and management level, including as the former CFO at Baxalta, Inc. (acquired by Shire plc in 2016), Director at Embecta Corporation (spun out of Becton, Dickinson and Company in 2022), Director at Naurex, Inc. (acquired by Allergan, Inc.), and Director at Surgical Innovation Associates (acquired by Integra LifeSciences Holdings Corporation)
• Operations: served as Baxalta, Inc.’s COO and had direct responsibility for operations, including manufacturing, quality, and the entire supply chain in addition to his CFO responsibilities
• Public Company Board and Governance Experience: service as Chair of the Audit Committee on public company boards includes BioMarin Pharmaceutical Inc., Embecta Corporation, and previously Aptinyx, Inc. Mr. Hombach also previously served as a member of the Audit Committee at CarMax, Inc. and in 2022 was recognized as a Board Leadership Fellow by the National Association of Corporate Directors (NACD)

Other Boards

• Seaport Therapeutics (March 2025 – Present) (Audit Committee Chair) (private)
• BioMarin Pharmaceutical, Inc. (2017 – Present) (Audit Committee Chair and Compensation Committee member)
• Embecta Corporation (2022 – Present) (Audit Committee Chair and Compensation and Management Development Committee member)
• Aptinyx, Inc. (2018 – 2023)
• CarMax, Inc. (2018 – 2022)
• Naurex, Inc. (2012 – 2015) (private)
• Surgical Innovation Associates, Inc. (2017 – 2022) (private)

Organizations

• Former Board Member, Loyola University Health System
• Former President and Chairman of the Board, Baxter International Foundation

Education

• CERT Certificate, Cyber-Risk Oversight, Carnegie Mellon University
• M.B.A., Northwestern University (Finance & Management Strategy)
• B.S., University of Colorado, Boulder (Finance)